Zoetis Inc. $ZTS Shares Purchased by Capital Analysts LLC

Key Points

• Capital Analysts LLC increased its stake in Zoetis Inc. by 7.9%, acquiring an additional 4,562 shares, bringing its total holdings to 62,275 shares worth approximately $10.25 million.
• Zoetis reported an earnings per share (EPS) of $1.76 for the recent quarter, surpassing the consensus estimate by $0.14, with a revenue of $2.46 billion, up 4.2% year-over-year.
• The company announced a quarterly dividend of $0.50 per share, representing an annualized dividend of $2.00 and a yield of 1.3%, with a payout ratio of 34.42%.

Capital Analysts LLC boosted its position in Zoetis Inc. (NYSE:ZTS - Free Report) by 7.9% in the 1st quarter, according to its most recent filing with the SEC. The firm owned 62,275 shares of the company's stock after acquiring an additional 4,562 shares during the period. Capital Analysts LLC's holdings in Zoetis were worth $10,254,000 at the end of the most recent reporting period.

A number of other large investors also recently made changes to their positions in ZTS. Brighton Jones LLC lifted its position in Zoetis by 180.4% during the fourth quarter. Brighton Jones LLC now owns 4,629 shares of the company's stock worth $754,000 after buying an additional 2,978 shares during the period. XTX Topco Ltd acquired a new position in shares of Zoetis during the 4th quarter valued at about $216,000. First Trust Advisors LP lifted its holdings in shares of Zoetis by 134.8% during the 4th quarter. First Trust Advisors LP now owns 104,496 shares of the company's stock worth $17,026,000 after acquiring an additional 59,990 shares during the period. Alta Advisers Ltd increased its position in Zoetis by 26.9% during the fourth quarter. Alta Advisers Ltd now owns 1,523 shares of the company's stock worth $248,000 after purchasing an additional 323 shares during the last quarter. Finally, Pinebridge Investments L.P. increased its position in Zoetis by 64.1% during the fourth quarter. Pinebridge Investments L.P. now owns 167,301 shares of the company's stock worth $27,258,000 after purchasing an additional 65,342 shares during the last quarter. Hedge funds and other institutional investors own 92.80% of the company's stock.

Zoetis Trading Up 2.1%

Shares of ZTS opened at $155.5170 on Wednesday. The company has a debt-to-equity ratio of 1.05, a current ratio of 1.76 and a quick ratio of 1.04. Zoetis Inc. has a 12 month low of $139.70 and a 12 month high of $200.33. The stock has a market cap of $68.92 billion, a PE ratio of 26.77, a P/E/G ratio of 2.44 and a beta of 0.88. The stock's 50-day moving average is $154.46 and its two-hundred day moving average is $158.88.

Zoetis (NYSE:ZTS - Get Free Report) last announced its earnings results on Tuesday, August 5th. The company reported $1.76 EPS for the quarter, beating the consensus estimate of $1.62 by $0.14. The business had revenue of $2.46 billion for the quarter, compared to the consensus estimate of $2.41 billion. Zoetis had a return on equity of 56.90% and a net margin of 27.83%.The company's revenue was up 4.2% on a year-over-year basis. During the same period last year, the business posted $1.56 EPS. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. Equities analysts forecast that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, September 3rd. Stockholders of record on Friday, July 18th will be given a dividend of $0.50 per share. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.3%. The ex-dividend date of this dividend is Friday, July 18th. Zoetis's payout ratio is presently 34.42%.

Analyst Upgrades and Downgrades

ZTS has been the subject of several research reports. Leerink Partners cut shares of Zoetis from an "outperform" rating to a "market perform" rating and lowered their price objective for the company from $180.00 to $155.00 in a research note on Thursday, July 17th. UBS Group lowered their price target on Zoetis from $189.00 to $170.00 and set a "neutral" rating for the company in a research report on Wednesday, May 7th. Leerink Partnrs downgraded Zoetis from a "strong-buy" rating to a "hold" rating in a report on Thursday, July 17th. Stifel Nicolaus cut Zoetis from a "buy" rating to a "hold" rating and decreased their target price for the stock from $165.00 to $160.00 in a report on Wednesday, June 18th. Finally, Piper Sandler increased their target price on shares of Zoetis from $210.00 to $215.00 and gave the stock an "overweight" rating in a research report on Monday, August 11th. Four analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $202.43.

Insider Buying and Selling at Zoetis

In related news, EVP Roxanne Lagano sold 652 shares of the firm's stock in a transaction on Tuesday, June 3rd. The shares were sold at an average price of $170.00, for a total transaction of $110,840.00. Following the completion of the sale, the executive vice president directly owned 15,129 shares of the company's stock, valued at approximately $2,571,930. This trade represents a 4.13% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 0.16% of the company's stock.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.